Quarterly ResultMay 13, 2026, 04:12 PM
ClearPoint Neuro Q1 Revenue $12.1M, up 43%; 25% Organic Devices Growth
AI Summary
ClearPoint Neuro, Inc. reported record first-quarter 2026 revenue of $12.1 million, a 43% increase year-over-year, driven by 25% organic growth in devices and the integration of IRRAflow. The company achieved a gross margin of 64% and made significant operational progress, including FDA clearance for its Velocity Alpha MR High Speed Surgical Drill System and Health Canada approval for its Neuro Navigation System. Despite these gains, the net loss widened to $9.552 million, and operating expenses increased by 44% due to the IRRAS acquisition. The company maintains its 2026 revenue guidance of $52.0 million to $56.0 million.
Key Highlights
- Q1 2026 revenue reached $12.1 million, marking a 43% year-over-year increase.
- Achieved 25% organic growth in devices revenue for the quarter.
- Gross margin expanded to 64% in Q1 2026, up from 60% in Q1 2025.
- Neurosurgery navigation, therapy and access revenue increased 80% to $5.9 million.
- Operating expenses rose 44% to $16.2 million, primarily due to the IRRAS acquisition.
- Reported a net loss of $(9.552) million for the quarter.
- Cash and cash equivalents totaled $35.6 million as of March 31, 2026.
- Reaffirmed 2026 revenue guidance between $52.0 million and $56.0 million.